Search Results - Protheroe, A

Renal and Adrenal Tumours by Protheroe, A

Get full text Get full text

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma by Fairfax, BP, Pratap, S, Roberts, ISD, Collier, J, Kaplan, R, Meade, AM, Ritchie, AW, Eisen, T, Macaulay, VM, Protheroe, A

Get full text Get full text Get full text

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer by Madhusudan, S, Protheroe, A, Propper, D, Han, C, Corrie, P, Earl, H, Hancock, B, Vasey, P, Turner, A, Balkwill, F, Hoare, S, Harris, A L

Get full text Get full text Get full text

A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol by Shamash, J, Powles, T, Sarker, S J, Protheroe, A, Mithal, N, Mills, R, Beard, R, Wilson, P, Tranter, N, O'Brien, N, McFaul, S, Oliver, T

Get full text Get full text Get full text

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer by Khan, O A, Blann, A D, Payne, M J, Middleton, M R, Protheroe, A S, Talbot, D C, Taylor, M, Han, C, Patil, M, Harris, A L

Get full text Get full text Get full text

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate by Khan, O A, Blann, A D, Payne, M J, Middleton, M R, Protheroe, A S, Talbot, D C, Taylor, M, Han, C, Patil, M, Harris, A L

Get full text Get full text

Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer by Protheroe, A S, Banks, R E, Mzimba, M, Porter, W H, Southgate, J, Singh, P N, Bosomworth, M, Harnden, P, Smith, P H, Whelan, P, Selby, P J

Get full text Get full text Get full text

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer by Khan, O A, Blann, A D, Payne, M J, Middleton, M R, Protheroe, A S, Talbot, D C, Taylor, M, Kirichek, O, Han, C, Patil, M, Harris, A L

Get full text Get full text

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapi... by Macaulay, V. M., Middleton, M. R., Protheroe, A. S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.-Y., LoRusso, P., Mery-Mignard, D., Soria, J.-C.

Get full text Get full text Get full text

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population by Illing, R O, Kennedy, J E, Wu, F, ter Haar, G R, Protheroe, A S, Friend, P J, Gleeson, F V, Cranston, D W, Phillips, R R, Middleton, M R

Get full text Get full text Get full text

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours by Blagden, S P, Molife, L R, Seebaran, A, Payne, M, Reid, A H M, Protheroe, A S, Vasist, L S, Williams, D D, Bowen, C, Kathman, S J, Hodge, J P, Dar, M M, de Bono, J S, Middleton, M R

Get full text Get full text Get full text

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer by Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., Boysen, G., Porta, N., Flohr, P., Gillman, A., Figueiredo, I., Paulding, C., Seed, G., Jain, S., Ralph, C., Protheroe, A., Hussain, S., Jones, R., Elliott, T., McGovern, U., Bianchini, D., Goodall, J., Zafeiriou, Z., Williamson, C.T., Ferraldeschi, R., Riisnaes, R., Ebbs, B., Fowler, G., Roda, D., Yuan, W., Wu, Y.-M., Cao, X., Brough, R., Pemberton, H., A’Hern, R., Swain, A., Kunju, L.P., Eeles, R., Attard, G., Lord, C.J., Ashworth, A., Rubin, M.A., Knudsen, K.E., Feng, F.Y., Chinnaiyan, A.M., Hall, E., de Bono, J.S.

Get full text Get full text Get full text

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol by Sydes, M R, Spears, M R, Mason, M D, Clarke, N W, Dearnaley, D P, de Bono, J S, Attard, G, Chowdhury, S, Cross, W, Gillessen, S, Malik, Z I, Jones, R, Parker, C C, Ritchie, A W S, Russell, J M, Millman, R, Matheson, D, Amos, C, Gilson, C, Birtle, A, Brock, S, Capaldi, L, Chakraborti, P, Choudhury, A, Evans, L, Ford, D, Gale, J, Gibbs, S, Gilbert, D C, Hughes, R, McLaren, D, Lester, J F, Nikapota, A, O’Sullivan, J, Parikh, O, Peedell, C, Protheroe, A, Rudman, S M, Shaffer, R, Sheehan, D, Simms, M, Srihari, N, Strebel, R, Sundar, S, Tolan, S, Tsang, D, Varughese, M, Wagstaff, J, Parmar, M K B, James, N D

Get full text Get full text Get full text

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy by James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Ritchie, A.W.S., Amos, C.L., Gilson, C., Jones, R.J., Matheson, D., Millman, R., Attard, G., Chowdhury, S., Cross, W.R., Gillessen, S., Parker, C.C., Russell, J.M., Berthold, D.R., Brawley, C., Adab, F., Aung, S., Birtle, A.J., Bowen, J., Brock, S., Chakraborti, P., Ferguson, C., Gale, J., Gray, E., Hingorani, M., Hoskin, P.J., Lester, J.F., Malik, Z.I., McKinna, F., McPhail, N., Money-Kyrle, J., O’Sullivan, J., Parikh, O., Protheroe, A., Robinson, A., Srihari, N.N., Thomas, C., Wagstaff, J., Wylie, J., Zarkar, A., Parmar, M.K.B., Sydes, M.R.

Get full text Get full text Get full text

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial by Clarke, N W, Ali, A, Ingleby, F C, Hoyle, A, Amos, C L, Attard, G, Brawley, C D, Calvert, J, Chowdhury, S, Cook, A, Cross, W, Dearnaley, D P, Douis, H, Gilbert, D, Gillessen, S, Jones, R J, Langley, R E, MacNair, A, Malik, Z, Mason, M D, Matheson, D, Millman, R, Parker, C C, Ritchie, A W S, Rush, H, Russell, J M, Brown, J, Beesley, S, Birtle, A, Capaldi, L, Gale, J, Gibbs, S, Lydon, A, Nikapota, A, Omlin, A, O'Sullivan, J M, Parikh, O, Protheroe, A, Rudman, S, Srihari, N N, Simms, M, Tanguay, J S, Tolan, S, Wagstaff, J, Wallace, J, Wylie, J, Zarkar, A, Sydes, M R, Parmar, M K B, James, N D

Get full text Get full text Get full text

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: A... by Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones, R.J., Langley, R.E., MacNair, A., Malik, Z., Mason, M.D., Matheson, D., Millman, R., Parker, C.C., Ritchie, A.W.S., Rush, H., Russell, J.M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O’Sullivan, J.M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N.N., Simms, M., Tanguay, J.S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M.R., Parmar, M.K.B., James, N.D.

Get full text Get full text Get full text